Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Ryan B. Corcoran(Massachusetts General Hospital), Geoffrey I. Shapiro(Brigham and Women's Hospital), Ryan J. Sullivan(Dana-Farber Cancer Institute), Gianluca Mauri(University of Milan), James M. Cleary(Brigham and Women's Hospital), Keith T. Flaherty(Cancer Research Center), Jennifer Veneris, Colin D. Weekes(Massachusetts General Hospital), Bryanna L. Norden(Massachusetts General Hospital), Giulia Siravegna(University of Turin), Aparna R. Parikh(Massachusetts General Hospital), Joan S. Brugge(Harvard University), Gary Chi(Harvard University), Helen X. Chen(National Cancer Institute), Leanne G. Ahronian(Harvard University), 俊彦 上田(Massachusetts General Hospital), Ursula A. Matulonis(Dana-Farber Cancer Institute), Niya Xiong(Dana-Farber Cancer Institute), Joyce F. Liu(Duke University), Rebecca S. Heist(Massachusetts General Hospital), T. Khanh(Brigham and Women's Hospital), Alexa Michel(Harvard University), Naoko Takebe(National Cancer Institute), Isobel J. Fetter(Harvard University), Dejan Juric(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Richard T. Penson(Massachusetts General Hospital), Emily E. Van Seventer(Massachusetts General Hospital), Oladapo Yeku(Harvard University), Jeong Eun Kim(Asan Medical Center), Kyle Camphausen(Massachusetts General Hospital)
Clinical Cancer Research
March 8, 2024
Cited by 39


Related Papers